RxDoctor Payments Data

Toby Campbell

Medical Oncology · Madison, WINPI 1700802220

Payments from drug & device makers

What this record shows

This record is dominated by speaking fees: $7,550 of the $11,888 with a category attached, or 63.5%. 4 manufacturers reported payments, led by Novocure Inc. at 47.5% of the total.

$11,888in general payments, 2019–2025

Across 13 payments — averaging $914.47 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novocure Inc.$6K
  • Genentech USA, Inc.$3K
  • E.r. Squibb & Sons, L.L.C.$3K
  • Novocure GmbH$200
$629,005in research payments, 2019–2025

Across 33 payments — averaging $19,061 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Merck$349K
  • Mirati Therapeutics, Inc.$146K
  • AbbVie$80K
  • Novocure Inc.$54K

What the payments were for

  • Consulting fees$3,04026%
  • Speaking & faculty fees$7,55064%
  • Travel & lodging$1,0129%
  • Food & beverage$2862%

General payments by program year

22
23

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$11,888 in reported general payments places this provider in the 85th percentile of 54 medical oncology providers in Wisconsin.

See all medical oncology providers in Wisconsin

Medicare billing

Part B allowed, 2024
$57,149
Medicare patients
195
Services billed
990

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
TagrissoOsimertinib Mesylate72$1,182,579
AlecensaAlectinib Hcl26$385,589
ZykadiaCeritinib11$92,159
EliquisApixaban19$13,167
Dexamethasone70$1,094
Ondansetron Hcl71$815
Oxycodone Hcl54$722
Morphine Sulfate ErMorphine Sulfate26$689
Morphine Sulfate20$674
Prochlorperazine Maleate43$493
Hydrocortisone14$348
Potassium Chloride17$298
Levothyroxine Sodium50$247
Escitalopram Oxalate15$178
Olanzapine22$163

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Genentech USA, Inc.Alecensa$3,040$385,58926 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 54 medical oncology providers in Wisconsin.

Other medical oncology in Madison

See the full list for Wisconsin

Where these figures come from

Is this you, or does something look wrong? →